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Long-Term Survival of Individuals Born With Congenital Heart
Disease: A Systematic Review and Meta-Analysis
Katie E. Best, PhD; Judith Rankin, PhD
Background-—Estimates of long-term survival are required to adequately assess the variety of health and social services required
by those with congenital heart disease (CHD) throughout their lives.
Methods and Results-—Medline, Embase, and Scopus were searched from inception to June 2015 using MeSH headings and
keywords. Population-based studies that ascertained all persons born with CHD within a predefined area and reported survival
estimates at ≥5 years were included. Unadjusted survival estimates for each CHD subtype at ages 1 year, 5 years, 10 years, and so
forth were extracted. Pooled survival estimates for each age were calculated using meta-analyses. Metaregression was performed
to examine the impact of study period on survival. Of 7840 identified articles, 16 met the inclusion criteria. Among those with CHD,
pooled 1-year survival was 87.0% (95% CI 82.1–91.2), pooled 5-year survival was 85.4% (95% CI 79.4–90.5), and pooled 10-year
survival was 81.4% (95% CI 73.8–87.9). There was significant heterogeneity of survival estimates among articles (P<0.001 for 1-, 5-,
and 10-year survival). A more recent study period was significantly associated with greater survival at ages 1 year (P=0.047), 5 years
(P=0.013), and 10 years (P=0.046). Survival varied byCHD subtype, with 5-year survival being greatest for thosewith ventricular septal
defect (96.3%, 95% CI 93.7–98.2) and lowest for those with hypoplastic left heart (12.5%, 95% CI 0.0–41.4).
Conclusions-—Among persons with CHD, the mortality rate is greatest during the first year of life; however, this systematic review
and meta-analysis showed that survival decreases gradually after infancy and into adulthood. ( J Am Heart Assoc. 2016;5:
e002846 doi: 10.1161/JAHA.115.002846)
Key Words: congenital • heart defects • survival
C ongenital heart disease (CHD) composes the largest groupof congenital anomalies and affects 1% of births in the
United States and Europe.1–3 CHD is a leading cause of stillbirth
and infant death and accounts for 4.2% of neonatal deaths in the
United States.4 Babies with severe CHD subtypes require
complex surgeries for survival. With advances in medical,
surgical, and intensive care interventions, an estimated 83% of
babies with CHD now survive infancy in the United States.5
Although 1-year survival estimates have been described,3,6–11
long-term survival estimates are not well researched, and
survival may continue to decrease into adulthood.
A previous systematic review of the long-term progno-
sis of CHD included only hospital-based studies that
ascertained cases postsurgically or in adulthood; estimates
were not representative of all persons with CHD.12 We
conducted a systematic review and meta-analysis of
population-based studies reporting long-term survival of
persons born with CHD. The aim was to assess and
quantify long-term survival to inform health services
planning and decision making.
Methods
Search Strategy
We conducted comprehensive literature searches of Medline,
Embase, and Scopus from inception (1946, 1974, and 1996,
respectively) to June 18, 2015. MeSH terms and keywords
were entered systematically into the databases. The keywords
included congenital and heart or cardiac or cardiovascular and
subject heading searches such as “exp Heart Defects,
Congenital/ep, mo” but varied according to database. The
list of search terms is available from the authors.
After systematic searches of each database, the citations
were extracted, and titles and abstracts were screened
according to the inclusion criteria. Full articles were retrieved
for all relevant citations. Reference lists of included articles
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were scanned and examined, and key journals were searched
using keywords.
Inclusion Criteria
Population-based original studies were included if they (1)
ascertained all persons born with CHD within a predefined
geopolitical area; (2) reported survival estimates (or the
number of patients born and the number or proportion alive)
at age ≥5 years; (3) reported survival estimates for all CHD
combined or a single CHD subtype including ventricular septal
defect, pulmonary valve stenosis, atrial septal defect, aortic
valve atresia or stenosis, atrioventricular septal defect,
coarctation of aorta, common arterial truncus, pulmonary
valve atresia (with ventricular septal defect or with intact
ventricular septum), tetralogy of Fallot, total anomalous
pulmonary venous return, transposition of great vessels,
tricuspid atresia, single ventricle, hypoplastic left heart, and
Ebstein’s anomaly; (4) were available from the British Library
or the Internet and were written in the English language.
Exclusion Criteria
Articles were excluded if patients were not followed from birth
(eg, follow-up began in adulthood or after surgical correction);
patients were not born in well-defined regions (ie, hospital-
based); survival was not estimated as a proportion of those
born with CHD (eg, age-specific population mortality rates);
survival was reported only for certain subtype groups (eg,
“severe” CHD). For multiple articles reported on the same
data set, the largest study or the study with the most recent
study period was included. Both articles were included if they
reported survival for different CHD subtypes or ages.
Data Extraction
K.E.B. performed the literature searches, screened citations,
and reviewed 40 full papers. J.R. screened 10% of the titles
and all abstracts to confirm decisions about inclusion, and
extracted data from all included papers. There were no
discrepancies between reviewers regarding article inclusion.
Study characteristics including study design, quality, data
sources, prevalence estimates, and the percentage of cases
with extracardiac anomalies (ie, cases of CHD occurring with
another congenital anomaly not of the cardiovascular system,
such as Down syndrome or cleft lip) were extracted from each
article. If it was unclear whether cases with extracardiac
anomalies were included, the authors were contacted.
Kaplan–Meier survival estimates and corresponding 95% CIs
were obtained from each included study at ages 1 year, 5 years,
10 years, and so forth. If 95% CIs were not reported, the authors
were contacted. If this was unsuccessful, the number of
patients born and the proportion that survived were used to
estimate binomial 95% CIs, assuming no cases were censored.
Survival estimates for all CHD subtypes combined and for each
CHD subtype were extracted. If survival estimates were
presented only graphically, the authors were contacted for
survival estimates. If this was unsuccessful, survival estimates
were extracted using Plot Digitizer software.13,14
Statistical Analysis
If there were at least 3 studies reporting survival, pooled
estimates of survival were calculated using ameta-analysis with
random effects. Weighting for each article was allocated using
the inverse of the variance. If the number of studies is small, the
estimation of between-study variance is thought to be impre-
cise in random-effects models.15 Consequently, if there were
only 3 studies reporting survival, the pooled survival was also
estimated using fixed-effects meta-analysis to allow compari-
son. To stabilize the variance and adjust the study weights, a
simplified double-arcsine transformation was performed on the
survival estimates and 95% CIs.16 The Cochrane Q test and the
I2 statistic were used to test for heterogeneity in survival
estimates between articles, with I2>50% indicating substantial
heterogeneity.17 Random-effects metaregression was per-
formed for all CHD subtypes combined to assess year of
delivery as a source of heterogeneity. In this analysis, the year in
which the study commenced was used as an explanatory
variable. The adjusted R2 value was used to estimate the
proportion of between-article variation accounted for by the
year of study commencement. A bubble plot was used to
present the fitted metaregression model. In this analysis,
bubbles represent each article, with sizes dependent on the
Figure 1. Preferred Reporting Items for Systematic Reviews and
Meta-Analyses diagram for the flow of articles through the review.
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precision of the survival estimates. Publication bias was
assessed with the Egger test.18
Analysis was performed in Stata 13 (StataCorp), and
P<0.05 was considered statistically significant.
Quality Appraisal
Quality appraisal was based on 4 of the 6 domains developed
by Hayden et al to assess potential bias in systematic reviews
of prognostic studies.19 The domains used were study
ascertainment, study attrition, outcome ascertainment, and
analysis. The domains relating to confounding and prognostic
factors were not relevant to this review because the primary
aim was to investigate unadjusted survival estimates.
Results
Figure 1 shows a Preferred Reporting Items for Systematic
Reviews and Meta-Analyses diagram for the flow of articles
through the review. Of 7840 identified articles, 16 met the
inclusion criteria.20–35
Study Characteristics
All included studies were conducted in high-income Western
populations, with 10 in Europe and 6 in the United States
(Table 1). Although several articles reported survival of subsets
of the same population, all were included because survival was
reported for different CHD subtypes or at different ages. The
oldest article included patients born between 1973 and 1997,22
and the most recent article included patients born between
1991 and 2007.35 Of the 16 included articles, 9 included cases
with extracardiac anomalies, with20% of cases occurringwith
other congenital anomalies in each article.23–26,28,30,33–35 Four
articles excluded patients with trisomy 13 (Patau syndrome)
and 18 (Edward syndrome) only.21,22,27,29 Two articles excluded
cases of CHD with any extracardiac anomalies,20,32 and 1 did
not state whether cases with extracardiac anomalies were
included.31 Prevalence estimates were reported by most
studies and ranged from 3.730 to 10.226 per 1000 live births
when considering all CHD as a composite group.
Survival Estimates
Survival was reported to age 5 years in 5 articles,20,21,23,28,29
to age 8 years in 1 article,35 to age 10 years in 3 articles,25–27
to age 15 years in 2 articles,22,31 to age 20 years in 1
article,32 to age 25 years in 3 articles,30,33,34 and to age 30
years in 1 article.24
For all CHD (as a composite group), pooled 1-year survival
from 6 articles was 87.0% (95% CI 82.1–91.2), pooled 5-year
survival from 8 articles was 85.4% (95% CI 79.4–90.5), and
pooled 10-year survival from 4 articles was 81.4% (95% CI
73.8–87.9) (Figure 2). It was not possible to pool estimates
beyond 10 years because there were too few articles;
however, Figure 3 shows the survival estimates plotted over
increasing age, up to age 25 years. The fitted metaregression
showed that survival decreases very gradually with increasing
age over 25 years. There was no evidence of publication bias
according to Egger tests (P=0.748 for 1 year, P=0.237 for
5 years, and P=0.601 for 10 years). There was significant
Figure 2. Forest plot for all congenital heart disease at ages 1, 5,
and 10 years.
Figure 3. Bubble plot of survival estimates for all congenital heart
disease at ages 1 to 25 years.
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heterogeneity between articles for survival at 1 year
(I2=99.0%, P<0.001), 5 years (I2=99.6%, P<0.001), and
10 years (I2=99.5%, P<0.001). Metaregression showed that
a more recent study period was significantly associated with
increased 1-, 5-, and 10-year survival (P=0.047, P=0.013, and
P=0.046, respectively) (Figure 4). According to the adjusted
R2 values, study period accounted for 50.9%, 62.8%, and
87.0% of the between-article variance for 1-, 5-, and 10-year
survival. After adjustment for study period, however, sub-
stantial residual heterogeneity remained that was attributable
to between-study heterogeneity (I2=98.2% at age 1 year,
I2=98.4% for survival at age 5 years, and I2=93.7% for survival
at age 10 years).
Table 2 shows the survival estimates and pooled survival
estimates for persons with CHD by subtype. Pooled 1-year
survival was lowest for those with hypoplastic left heart (17.4%,
95% CI 0.0–54.5) and greatest for those with ventricular septal
defect (95.5%, 95% CI 89.0–99.2). There was significant
heterogeneity of survival estimates among articles for all CHD
subtypes, with the exception of tetralogy of Fallot (I2=0%,
P=0.169). Heterogeneity of estimates for single ventricle was of
borderline statistical significance (I2=65.0%, P=0.057). Pooled
5-year survival varied by subtype, with survival for hypoplastic
left heart at 12.5% (95% CI 0.0–41.4) and survival for ventricular
septal defect at 97.7% (95% CI 93.5–99.8). With the exception
of tetralogy of Fallot (I2=0.0%, P=0.957) and single ventricle
(I2=26.9%, P=0.250), there was significant heterogeneity of
survival estimates among articles (Table 2). It was possible to
calculate pooled 15-year survival estimates for aortic valve
atresia or stenosis, atrioventricular septal defect, common
arterial truncus, and coarctation of aorta but not for any other
CHD subtypes. There were too few studies to calculate pooled
survival beyond age 15 years, although in the few studies that
reported survival into adulthood, survival was still gradually
declining.
For subtypes for which just 3 studies reported survival,
pooled estimates were also calculated using fixed-effect
meta-analysis (Table 2). Pooled survival estimates were
generally similar for the random- and fixed-effects models,
with the exception of the 10- and 15-year pooled estimates
for common arterial trunk (28.9% versus 35.4% and 36.5%
versus 54.4%, respectively).
Quality Appraisal
Quality appraisal is shown in Table 3. All articles satisfied the
study ascertainment domain because, by definition, popula-
tion-based studies are representative of the population. The
attrition domain was satisfied by 31% of articles because of
studies failing to report the proportion of untraced cases;
however, many of the studies classed unmatched cases as
alive, so it is possible that all cases were traced. The outcome
ascertainment domain was satisfied by 94% of studies, and
the analysis domain was satisfied by 81%. Studies that did not
satisfy the analysis domain were those that did not perform
survival analysis and instead reported the proportion alive,
which does not account for case censorship. This may have
slightly inflated survival in these studies.
Figure 4. Bubble plots showing the association between study
period and survival for all congenital heart disease. A, 1-year
survival. B, 5-year survival. C, 10-year survival.
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Discussion
In this systematic review and meta-analysis, we found that
87.0% of individuals born with CHD survived to age 1 year,
85.4% survived to age 5 years, and 81.4% survived to age 10
years. Few studies reported survival beyond age 10 years, but
survival appeared to continue to gradually decrease into
adulthood. There was substantial variation in survival esti-
mates among articles, some of which was accounted for by
study period, which positively affected survival.
The main strength of this systematic review is its restriction
to population-based studies. Although including hospital-based
studies would have increased the amount of data available,
such studies underascertain milder CHD subtypes that do not
require major medical intervention. In addition, children with
severe CHD may travel to centers with specialist expertise;
therefore, the survival estimates reported by hospital-based
studies can be unrepresentative of the general population of
individuals with CHD. The robustness of the individual rates of
bias was examined using a quality assessment with previously
published domains and items.19 Although each study failed to
satisfy at least 1 quality item because of the population-based
study designs, the potential for bias in each domain remained
low. Moreover, for all CHD, we did not identify any significant
publication bias according to the Egger test.
A further strength is the comprehensive nature of our search
strategy. Three databases were searched for relevant citations,
along with key journals and reference lists; therefore, the
likelihood of missing key studies was limited. Full articles were
reviewed by both authors to ensure that they fully met the
inclusion criteria and that data were extracted correctly. A
further strength is thatwe reported pooled estimates calculated
from fixed- and random-effects meta-analyses if there were just
3 studies reporting survival. Random-effectsmeta-analysis may
calculate pooled estimates using an imprecise between-study
variance if the number of studies is low.15 The pooled estimates
from the fixed-effect meta-analyses were broadly similar to
those from the random-effects meta-analyses but with smaller
confidence intervals.
There were also several limitations. The maximum follow-
up was just 30 years, with 5 of the included studies
reporting survival to just 5 years. The greatest risk of death
occurred in infancy, but survival continued to decrease over
follow-up, although at a much lesser rate. A study of CHD-
related mortality rates between 1999 and 2006 in the
United States showed a high mortality rate of 41.5 per
100 000 in infancy, which decreased to 1.38 between ages
1 and 4 years and stabilized at 0.55 between the ages of
5 and 65 years. After age 65 years, the mortality rate
doubled to 1.10 per 100 000.36
A further limitation is that longer term survival estimates
may not be representative of children born with CHD today.
Even in the most recent studies, 25-year survival rates related
to persons born in the 1990s; in our metaregression of 1-, 5-,
and 10-year survival, we showed that survival estimates
improved over time.
All included studies were performed in high-income
Western populations. Evidence suggests that infant mortality
rates associated with congenital anomalies are greater in low-
income countries.37 Consequently, the survival estimates in
this review are not likely to be globally representative.
Although we included only articles written in the English
language, we did not identify any relevant articles written in
other languages.
Most of the included articles included cases with extrac-
ardiac anomalies20–31,33,34; therefore, it is difficult to assess
how much of the mortality was accounted for by CHD as
opposed to the co-occurring congenital anomalies. Neverthe-
less, cases with extracardiac anomalies accounted for only
20% of cases, and some extracardiac anomalies were not
likely to be life threatening; therefore, the impact on survival
is likely to be low. All articles used all-cause mortality,
meaning that deaths may not have been directly related to the
CHD diagnosis.
Although this review provides insight into long-term
mortality associated with CHD, we did not account for
morbidity. Research suggests that quality of life is lower in
those with CHD and that those who live with CHD can have
morbidities such as endocarditis, cerebrovascular accidents,
myocardial infarctions, and arrhythmias.38–40 The American
Heart Association has also reported that children with CHD
are at increased risk of developmental disorders.41 Research
suggests that children with CHD are more likely to require
special education services, regardless of CHD severity.42
In our metaregression, we found that a more recent study
period positively affected survival estimates; however, even
after adjustment for study period, there was still a high degree
of heterogeneity. Although we adjusted for study period using
the year of study commencement, the lengths of the study
periods varied by article; therefore, our adjustment for the year
of study commencement is not likely to have fully accounted for
the changes in survival over time. Further heterogeneity is likely
attributable to a variety of sources. Case ascertainment is likely
a major cause. Olsen et al reported lower survival estimates
even after accounting for study period, but their prevalence of
CHD was almost half that of other studies. Given that they
included only cases diagnosed before age 1 year, it is likely that
they underascertained cases with milder CHD subtypes, such
as ventricular septal defect.30 The data sources used may also
have contributed to variation in ascertainment, with articles
using hospital records as opposed to congenital anomaly
registers (which use multiple sources for ascertainment)
contributing to lower survival estimates, likely due to the milder
cases being underascertained.31
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Variation in study periods is arguably the greatest source
of heterogeneity for survival estimates. Survival has improved
over time because of advances in surgical correction. The
Fontan operation, for example, for repair of single ventricle,
hypoplastic left heart, and tricuspid atresia and the conduit
repair for cases of common arterial trunk were introduced in
the late 1970s and developed throughout the 1980s and
1990s.43,44 The arterial switch operation for treatment of
transposition of the great vessels was introduced in 197545
and fully replaced the atrial switch operations in the early
1990s, resulting in improved long-term survival.46 Survival is
also likely to have improved over time because of advances in
prenatal diagnosis. Greater prenatal diagnosis rates may have
led to an increase in rates of termination (for fetal anomaly). If
cases with the more severe subtypes were terminated, this
would have resulted in better survival. Prenatal diagnosis also
allows quicker intervention at birth or even in utero, which
may also improve survival.47 In addition, survival is likely to
have improved because of the introduction of prostaglandin,
which underwent trials in neonates with cyanotic CHD in the
1970s,48,49 although it was not frequently administered until
the 1980s.
The improvement in survival rates over time has led to an
emerging population of adolescents and adults with CHD.
These patients require long-term follow-up, sometimes lead-
ing to reinvestigation and reoperation. Consequently, popula-
tion-based surveillance of CHD is crucial to adequately assess
the variety of health and social services required by those with
CHD throughout their lives.
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